Solventum (NYSE:SOLV) Director Amy Mcbride Wendell Buys 1,475 Shares of Stock

Solventum Corporation (NYSE:SOLV) Director Amy Mcbride Wendell acquired 1,475 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was bought at an average price of $68.03 per share, with a total value of $100,344.25. Following the purchase, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Solventum Stock Performance

Shares of SOLV traded down $0.34 during midday trading on Thursday, reaching $67.28. 133,687 shares of the stock were exchanged, compared to its average volume of 1,093,972. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $88.20. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. The company has a market capitalization of $11.67 billion, a price-to-earnings ratio of 7.58, a PEG ratio of 1.11 and a beta of 0.40. The business’s 50-day moving average price is $76.91 and its 200 day moving average price is $76.08.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business’s revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, sell-side analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum declared that its Board of Directors has approved a share repurchase plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

SOLV has been the topic of several research reports. Wells Fargo & Company lowered their price objective on shares of Solventum from $86.00 to $83.00 and set an “equal weight” rating on the stock in a research report on Friday, February 27th. Stifel Nicolaus increased their price target on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Zacks Research downgraded shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Piper Sandler reissued an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Finally, Mizuho set a $100.00 price target on Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Seven research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $93.70.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Assetmark Inc. boosted its position in Solventum by 21.4% during the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after acquiring an additional 128 shares during the last quarter. Hilltop National Bank lifted its position in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares in the last quarter. Allworth Financial LP lifted its holdings in Solventum by 2.8% in the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after buying an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in Solventum by 0.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after purchasing an additional 134 shares in the last quarter. Finally, BOKF NA raised its position in shares of Solventum by 6.9% in the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after purchasing an additional 141 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.